LabCorp's Stock Soars After Q2 Performance, Analyst Highlights Strong Position In Healthcare Sector
LabCorp's Stock Soars After Q2 Performance, Analyst Highlights Strong Position In Healthcare Sector
Thursday, Laboratory Corp (NYSE:A) reported second-quarter 2024 adjusted EPS of $3.94, up from $3.42 a year ago, beating the consensus of $3.78.
紐交所:A股的實驗室公司在2024年第二季度報告了每股收益3.94美元，比去年同期的3.42美元上升，超過了3.78美元的共識。
Sales increased 6.2% year-over-year to $3.22 billion, beating the consensus of $3.19 billion.
營業收入同比增長6.2%至32.2億美元，超出了31.9億美元的共識。
The increase was due to organic revenue of 3.8%, acquisitions, and net of divestitures of 2.5%, partially offset by foreign currency translation of (0.1%).
增加是由於有機營收增長了3.8％，收購和減值後的淨額爲2.5％，部分抵消了貨幣匯率轉換的（0.1％）。
The 3.8% increase in organic revenue was driven by a 4.5% increase in the company's organic Base Business, partially offset by a (0.7%) decrease in COVID-19 testing.
有機營收增長3.8％，其中公司有機基礎業務增長了4.5％，部分抵消了COVID-19測試的下降0.7％。
Operating income for the quarter was $294.8 million, or 9.2% of revenue, compared to $266.3 million, or 8.8%, in the second quarter of 2023.
本季度運營收入爲29480萬美元，佔營業收入的9.2％，而2023年第二季度爲26630萬美元，佔營業收入的8.8％。
Diagnostics Laboratories revenue for the quarter was $2.52 billion, an increase of 7.9%.
診斷實驗室本季度營收爲25.2億美元，增長了7.9％。
Biopharma Laboratory Services revenue increased 1.1% to $707.0 million.
生物製藥實驗室服務營收增長了1.1％至70700萬美元。
Guidance: LabCorp cuts its 2024 adjusted EPS outlook from $14.45-$15.35 to $14.30-$14.90, compared to the consensus of $14.82.
指引：LabCorp將其2024年調整後每股收益預期從14.45-15.35美元下調到14.30-14.90美元，而共識預期爲14.82美元。
The company raised the 2024 revenue growth outlook from 4.8%- 6.4% to 6.4%- 7.5%, compared to the consensus of $12.83 billion.
與共識預期的128.3億美元相比，公司將2024年的收入增長預期從4.8％-6.4％上調至6.4％-7.5％。
William Blair writes, "At first blush, there is not much to pick at in the quarter as modest revenue upside and margin expansion above expectation should be viewed positively."
William Blair寫道，“乍一看，季度裏沒有太多可以挑刺的地方，適度的營收增長和較高的利潤率應該受到肯定。”
With expectations slightly lowered compared to last week following Quest Diagnostics Incorporated's (NYSE:DGX) report, the analyst writes the update will help Labcorp shares maintain their current multiple of around 13 times the expected 2025 EPS.
由於Quest Diagnostics Incorporated (NYSE: DGX)的報告與上週相比稍有下降，分析師寫道，這次更新將幫助Labcorp股票維持目前的每股收益預期的13倍左右。
Although the reductions in profitability related to Invitae are slightly greater than anticipated, this should provide ample opportunity for Labcorp to demonstrate the long-term value of this acquisition.
儘管與預期略有不同，與Invitae相關的盈利降低應該爲Labcorp提供充足的機會來展示這筆收購的長期價值。
Labcorp remains well-positioned as a reliable and predictable growth company within the healthcare sector.
Labcorp仍然是醫療保健板塊內可靠和可預測的增長公司。
William Blair reiterates the Outperform rating.
William Blair重申Outperform評級。
Price Action: LH stock is up 6.10% at $228.59 at the last check on Thursday.
股票價格行動：上週四LH股票價格上漲6.10％，至每股228.59美元。
- Biogen Q2 Earnings: Beats Consensus, Lifts 2024 Profit Forecast As New Drug Launches Expected To Offset Decline In Multiple Sclerosis Med Sales.
- Biogen第二季度盈利：超過共識，提升2024年利潤預測，因爲預計新藥推出將抵消原有多發性硬化藥品銷售額下降。
Photo via Wikimedia Commons
照片通過Wikimedia Commons